Q4 2025 · 13F-HR
Monashee Investment Management LLCholdings as filed
Filed 2026-02-12 · accession 0001172661-26-000650
$177.5M
Reported value
40
Positions
2025-12-31
Period end
The Brief · Monashee Investment Management LLC · Q4 2025
AI · grounded in 13F
Monashee Investment Management LLC established a new position in MDLN valued at $12.6M. The fund also opened new stakes in SOFI for $10.47M and ULS for $10.25M. On the sell side, the manager closed its position in 23I, reducing exposure by $10.37M.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $15.6M | 8.82% | 225,000 | Common | SOLE |
| 58507V107 | MDLN | MEDLINE INC | $12.6M | 7.10% | 300,000 | Common | SOLE |
| 83406F102 | SOFI | SOFI TECHNOLOGIES INC | $10.5M | 5.90% | 400,000 | Common | SOLE |
| 903731107 | ULS | UL SOLUTIONS INC | $10.3M | 5.78% | 130,000 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $8.7M | 4.90% | 50,000 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $8.0M | 4.49% | 197,313 | Common | SOLE |
| 501575104 | KYMR | KYMERA THERAPEUTICS INC | $7.8M | 4.38% | 100,000 | Common | SOLE |
| 59356Q108 | MIAX | MIAMI INTL HLDGS INC | $7.8M | 4.38% | 175,000 | Common | SOLE |
| 10806X102 | BBIO | BRIDGEBIO PHARMA INC | $7.6M | 4.31% | 100,000 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $7.6M | 4.29% | 1,349,771 | Common | SOLE |
| 52476L109 | LGN | LEGENCE CORP | $5.9M | 3.35% | 137,940 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $5.9M | 3.33% | 274,861 | Common | SOLE |
| 45073V108 | ITT | ITT INC | $5.6M | 3.14% | 32,067 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $5.4M | 3.03% | 1,000,000 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $4.8M | 2.69% | 75,000 | Common | SOLE |
| 947002101 | WLTH | WEALTHFRONT CORP | $4.1M | 2.30% | 300,000 | Common | SOLE |
| 640268306 | NKTR | NEKTAR THERAPEUTICS | $4.0M | 2.24% | 94,134 | Common | SOLE |
| 842587842 | SO 7.125 12/15/28 A | SOUTHERN CO | $3.8M | 2.15% | 75,877 | Common | SOLE |
| 00090Q103 | ADT | ADT INC DEL | $3.2M | 1.82% | 400,000 | Common | SOLE |
| 30054Y107 | EVMN | EVOMMUNE INC | $3.1M | 1.77% | 183,239 | Common | SOLE |
| 38341P102 | GOSS | GOSSAMER BIO INC | $3.1M | 1.75% | 1,000,000 | Common | SOLE |
| 67000B203 | NOVT 6.5 11/01/28 | NOVANTA INC | $3.1M | 1.73% | 55,962 | Common | SOLE |
| 550249106 | LMRI | LUMEXA IMAGING HOLDINGS INC | $2.8M | 1.56% | 150,000 | Common | SOLE |
| 29286M105 | — | ENGENE HOLDINGS INC | $2.7M | 1.50% | 295,000 | Common | SOLE |
| 023193105 | AMBQ | AMBIQ MICRO INC | $2.4M | 1.37% | 85,089 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $2.2M | 1.26% | 114,525 | Common | SOLE |
| G96115103 | WYFI | WHITEFIBER INC | $2.2M | 1.25% | 140,000 | Common | SOLE |
| 40054J109 | AERO | GRUPO AEROMEXICO SAB DE CV | $2.0M | 1.13% | 91,619 | Common | SOLE |
| G3106Q110 | EVAC/U | EQV VENTURES AC CORP. II | $2.0M | 1.13% | 198,313 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $1.8M | 1.03% | 195,000 | Common | SOLE |
| N44445109 | IMTX | IMMATICS N.V | $1.7M | 0.95% | 160,336 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC | $1.6M | 0.89% | 137,430 | Common | SOLE |
| 24823R105 | DNLI | DENALI THERAPEUTICS INC | $1.5M | 0.85% | 91,620 | Common | SOLE |
| 38341PAA0 | GOSS 5 06/01/27 | GOSSAMER BIO INC | $1.3M | 0.72% | 1,874,000 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $1.2M | 0.65% | 22,905 | Common | SOLE |
| 532257805 | LPTH | LIGHTPATH TECHNOLOGIES INC | $1.1M | 0.61% | 100,000 | Common | SOLE |
| 09075X207 | BDSX | BIODESIX INC | $763,939 | 0.43% | 112,344 | Common | SOLE |
| 74365U107 | TARA | PROTARA THERAPEUTICS INC | $666,250 | 0.38% | 125,000 | Common | SOLE |
| 45175G207 | IMA | IMAGENEBIO INC | $632,185 | 0.36% | 91,621 | Common | SOLE |
| 451033708 | IBIO | IBIO INC | $530,484 | 0.30% | 274,862 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.